Evidence map›Paper›PMID 40093727›Full record

ArticleFrontiers in public health2025

Case series: Chemical pneumonitis caused by exposure of sodium ibandronate powder.

Ting Pan, Guofeng Ma, Jiali Qian

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ting Pan *Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Guofeng Ma *Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jiali QianDepartment of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report presents two cases of chemical pneumonitis caused by the exposure of sodium ibandronate powder, a bisphosphonate used for treating osteoporosis. They are both pharmaceutical workers, and they inhaled the powder after an accidental spill in the lab. They developed similar symptoms, but different imaging features, only one showed fibrotic changes. After the blood test and bronchoscopy examination, they both diagnosed as chemical pneumonitis. Their symptoms improved after treatment with glucocorticoids. Their lung lesions resolved completely after continued treatment. The findings suggest that the importance of appropriate safety measures in environments where pharmaceutical powders may be handled, such as in the pharmaceutical industry. Chemical pneumonitis from inhaled sodium ibandronate can have varying CT appearances and may benefit from glucocorticoids therapy.

Indexed as

Bone Density Conservation AgentsDiphosphonatesOccupational ExposurePneumoniaAgedFemaleGlucocorticoidsHumansIbandronic AcidMaleMiddle AgedOsteoporosisPowdersTomography, X-Ray ComputedBone Density Conservation AgentsDiphosphonatesGlucocorticoidsIbandronic AcidPowderscase reportchemical pneumonitisexposuresodium ibandronatesteroid treatment

Identifiers

PMID40093727
PMCPMC11906404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.